Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers

Neuropathology and Applied Neurobiology

Volumn 31, Issue 4, 2005, Pages 439-448

  Ramage, S N ^a   Anthony, I C ^a   Carnie, F W ^a   Busuttil, A ^a   Robertson, R ^b   Bell, Jeanne E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Muirhouse Medical Group   (United Kingdom)

Author keywords

Drug abuse; Human brain; Neuropathology; Opiate; Tau protein

Indexed keywords

ALCOHOL; AMITRIPTYLINE; AMPHETAMINE; AMYLOID PRECURSOR PROTEIN; BUPRENORPHINE; CANNABIS; DIAMORPHINE; DIAZEPAM; DIHYDROCODEINE; FLUOXETINE; LYSERGIDE; METHADONE; OPIATE; TAU PROTEIN; TEMAZEPAM;

ADOLESCENT; ADULT; ALCOHOL ABUSE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN EDEMA; BRAIN HYPOXIA; CANNABIS ADDICTION; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ABUSE; FEMALE; HEROIN DEPENDENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUBARACHNOID HEMORRHAGE;

ADOLESCENT; ADULT; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLES; PHOSPHORYLATION; SUBSTANCE-RELATED DISORDERS; TAU PROTEINS; UBIQUITIN;

EID: 23044451173     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2005.00670.x     Document Type: Article

References (49)

1. Drug-Related Deaths in Scotland in 2003. Occasional Paper 8. Edinburgh: General Register Office for Scotland, 2004.
2. Office for National Statistics. Deaths related to drug poisoning: results for England and Wales 1998-2002. Health Stat Q 2004; 21: 62-6
3. National Institute on Drug Abuse. Heroin Abuse and Addiction. NIDA Research Report Series, 2000.
4. Arango JC, Simmonds P, Brettle RP, Bell JE. Does drug abuse influence the microglial response in AIDS and HIV encephalitis? Aids 2004; 18 (Suppl. 1): S69-74
5. Bell JE, Arango JC, Robertson R, Brettle RP, Leen C, Simmonds P. HIV and drug misuse in the Edinburgh cohort. J Acquir Immune Defic Syndr 2002; 31 (Suppl. 2): S35-42
6. Bell JE, Donaldson YK, Lowrie S, McKenzie CA, Elton RA, Chiswick A, Brettle RP, Ironside JW, Simmonds P. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. Aids 1996; 10: 493-9
7. Egan V, Brettle RP, Goodwin GM. The Edinburgh cohort of HIV-positive drug users: pattern of cognitive impairment in relation to progression of disease. Br J Psychiatry 1992; 161: 522-31
8. Goodwin GM, Pretsell DO, Chiswick A, Egan V, Brettle RP. The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia. Aids 1996; 10: 431-40
9. Andersen SN, Skullerud K. Hypoxic/ischaemic brain damage, especially pallidal lesions, in heroin addicts. Forensic Sci Int 1999; 102: 51-9
10. Buttner A, Mall G, Penning R, Weis S. The neuropathology of heroin abuse. Forensic Sci Int 2000; 113: 435-42
11. Oehmichen M, Meissner C, Reiter A, Birkholz M. Neuropathology in non-human immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic intravenous drug abuse. Acta Neuropathol (Berl) 1996; 91: 642-6
12. Tomlinson GS, Simmonds P, Busuttil A, Chiswick A, Bell JE. Upregulation of microglia in drug users with and without pre-symptomatic HIV infection. Neuropathol Appl Neurobiol 1999; 25: 369-79
13. Zhang L, Looney D, Taub D, Chang SL, Way D, Witte MH, Graves MC, Fiala M. Cocaine opens the blood-brain barrier to HIV-1 invasion. J Neurovirol 1998; 4: 619-26
14. Gosztonyi G, Schmidt V, Nickel R, Rothschild MA, Camacho S, Siegel G, Zill E, Pauli G, Schneider V. Neuropathologic analysis of postmortal brain samples of HIV-seropositive and - seronegative i.v. drug addicts. Forensic Sci Int 1993; 62: 101-5
15. Bamberger ME, Landreth GE. Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist 2002; 8: 276-83
16. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 2002; 962: 318-31
17. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 741-9
18. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-32
19. Oken RJ, McGeer PL. Schizophrenia, Alzheimer's disease, and anti-inflammatory agents. Schizophr Bull 1996; 22: 1-4
20. Benveniste EN, Nguyen VT, O'Keefe GM. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int 2001; 39: 381-91
21. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004; 3: 169-76
22. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003; 304: 1-7
23. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 2004; 1: 14
24. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-7
25. Bell JE, Busuttil A, Ironside JW, Rebus S, Donaldson YK, Simmonds P, Peutherer JF. Human immunodeficiency virus and the brain: investigation of virus load and neuropathologic changes in pre-AIDS subjects. J Infect Dis 1993; 168: 818-24
26. Strappe PM, Wang TH, McKenzie CA, Lowrie S, Simmonds P, Bell E. Enhancement of immunohistochemical detection of HIV-1 p24 antigen in brain by tyramide signal amplification. J Virol Methods 1997; 67: 103-12
27. Cho JH, Johnson GV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 2004; 88: 349-58
28. Nakano H, Kobayashi K, Sugimori K, Shimazaki M, Miyazu K, Hayashi M, Furuta H. Regional analysis of differently phosphorylated tau proteins in brains from patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17: 122-31
29. Gelman BB, Schuenke K. Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. J Neurovirol 2004; 10: 98-108
30. Braak H, Del Tredici K. Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-beta formation. Neurobiol Aging 2004; 25: 713-18; discussion 743-6
31. Duyckaerts C. Looking for the link between plaques and tangles. Neurobiol Aging 2004; 25: 735-9; discussion 743-6
32. Terry RD. Tangles precede plaques but don't cause them. Neurobiol Aging 2004; 25: 741-2; discussion 743-6
33. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351-7
34. Geddes JF, Vowles GH, Nicoll JA, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol (Berl) 1999; 98: 171-8
35. Goedert M, Ghetti B, Spillantini MG. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann N Y Acad Sci 2000; 920: 74-83
36. Newman SJ, Gentleman SM, Graham DI, Brown F, Roberts GW. Tissue distribution and cellular localisation of hyperphosphorylated tau in human head injury and age-matched controls. In Research Advances in Alzheimer's Disease and Related Disorders. Eds K Iqbal, JA Mortimer, B Winblad, HM Wisniewski. Chichester; New York: Wiley, 1995; 439-403
37. Smith C, Graham DI, Murray LS, Nicoll JA. Tau immunohistochemistry in acute brain injury. Neuropathol Appl Neurobiol 2003; 29: 496-502
38. Tokuda T, Ikeda S, Yanagisawa N, Ihara Y, Glenner GG. Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid beta-protein and tau protein. Acta Neuropathol (Berl) 1991; 82: 280-5
39. Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM. Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis 2003; 5: 209-28
40. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003; 23: 1605-11
41. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004; 295: 245-57
42. Darke S, Ross J, Hall W. Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of nonfatal overdose. Addiction 1996; 91: 405-11
43. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004; 10 (Suppl.): S18-25
44. Katz LM, Young AS, Frank JE, Wang Y, Park K. Regulated hypothermia reduces brain oxidative stress after hypoxic-ischemia. Brain Res 2004; 1017: 85-91
45. Ulrich J, Johannson-Locher G, Seiler WO, Stahelin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol (Berl) 1997; 94: 450-4
46. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology 2002; 59: 398-407
47. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130
48. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-32
49. McKenzie KJ, McLellan DR, Gentleman SM, Maxwell WL, Gennarelli TA, Graham DI. Is beta-APP a marker of axonal damage in short-surviving head injury? Acta Neuropathol (Berl) 1996; 92: 608-13